Logo of the Cardio Pulmonary Institute (CPI)
Paper of the Month: Dezember 2024

ATP citrate lyase drives vascular remodeling in systemic and pulmonary vascular diseases through metabolic and epigenetic changes

Science
Grobs Y, Romanet C, Lemay S-E, Bourgeois A, Voisine P, Theberge C, Sauvaget M, Breuils-Bonnet S, Martineau S, El Kabbout R, Valasarajan C, Chelladurai P, Pelletier A, Mougin M, Dumais E, Perron J, Flamand N, Potus F, Provencher S, Pullamsetti SS, Boucherat O, Bonnet S

Exciting new research from the groups of Dr. Sebastian Bonnet and Dr. Soni Pullamsetti highlights ATP citrate lyase (ACLY) as a potential therapeutic target for vascular diseases, including pulmonary arterial hypertension (PAH). ACLY, a key enzyme in lipid synthesis and histone acetylation, has been shown to be upregulated in human coronary and pulmonary artery tissue from patients with coronary artery disease and PAH as well as in animal models of these diseases, leading to metabolic and epigenetic changes in vascular cells.

Through pharmacological inhibition and genetic inactivation, the team demonstrated that blocking ACLY reduces vascular remodeling and improves disease progression in several animal models. Excitingly, these results were also confirmed in ex vivo models such as human precision lung slices and saphenous vein rings, underlining the therapeutic potential of ACLY.

This study is one of the first to address the common mechanisms of systemic and pulmonary vascular diseases. It paves the way for targeting metabolic and epigenetic pathways in vascular disease and brings us one step closer to new treatment options for PAH.

 

Find the full article here:

ATP citrate lyase drives vascular remodeling in systemic and pulmonary vascular diseases through metabolic and epigenetic changes | Science Translational Medicine

Paper of the Month in Archive

CPI News
Academy News